In a report released today, Matthew Lillis from Cantor Fitzgerald maintained a Buy rating on Seres Therapeutics (MCRB), with a price target of $15. The company’s shares opened today at $6.13.
Lillis observed:
“We believe MCRB is well positioned to translate discoveries of how the microbiome is involved in human physiology into proprietary therapeutics to treat important diseases. Development of clinical assets is likely to be impacted by the need to generate empirical data that may not be required for “typical” drug development. Thus, we believe investors might should view early-stage proof-of-concept (POC) or proof-of-biology (POB) data as more meaningful than might otherwise be the case. We believe SER-109 for treating C. diffiicle infection (CDI) and SER-287 for treating ulcerative colitis (UC) will be the main drivers of share value.”
According to TipRanks.com, Lillis is a 2-star analyst with an average return of 1.2% and a 50.0% success rate. Lillis covers the Healthcare sector, focusing on stocks such as Taiwan Liposome Company Ltd, Supernus Pharmaceuticals, and Evofem Biosciences Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Seres Therapeutics with a $15.33 average price target.
See today’s analyst top recommended stocks >>
Based on Seres Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $21.95 million. In comparison, last year the company had a GAAP net loss of $28.95 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Seres Therapeutics, Inc. is a microbiome therapeutics platform company, which engages in the development of biological drugs. It focuses on implementing microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
